Artificial IntelliFrance
France is attempting to reposition itself as a globally competitive hub for artificial intelligence R&D, with significant state investment aiming to turn Paris into the next Palo Alto. With rapid…
Alfa Wassermann is a pharmaceutical group with an Italian heart and an international outlook. For over sixty years, it has researched, manufactured and distributed drugs of primary importance for human health, allowing people to benefit from new discoveries in medicine, biology and genomics. Today the Group operates in 12 different countries and employs approximately 1,370 employees, 670 of which in Italy.
Alfa Wassermann´s strategy is to focus on the gastro-intestinal area. Already present in IBS, constipation and diarrhoea, with the launch of Rifaximin-alpha 500 they will be active in a further major gastro-intestinal related area, namely hepatic encephalopathy. In France market authorization was received for Rifaximin-alpha 500mg in January 2015. Alfa Wassermann and its partner Norgine will jointly promote and manage the clinical development of Rifaximine alpha 550 mg in France.
Contact
ALFA WASSERMANN PHARMA SAS
67, rue Anatole France
92300 Levallois Perret – France
Ph. +33 1 41 27 25 10 – Fax +33 1 47 58 77 04
France is attempting to reposition itself as a globally competitive hub for artificial intelligence R&D, with significant state investment aiming to turn Paris into the next Palo Alto. With rapid…
Professor José-Alain Sahel, founder and director of the Institute de la Vision in Paris, offers his insider take on the ophthalmology landscape in France, international perceptions of the country, and…
Bertrand Letartre of Anios discusses the company’s rich history, their move towards more technical offerings with the acquisition of Soluscope, internationalization, family values, and the company’s mission to spread awareness…
In an exclusive interview, Agnès Buzyn, Chairwoman of the Board for the French National Authority for Health (Haute Autorité de Santé – HAS), on her organization’s priorities, the particularities of…
Shedding light on the unique business model of French pharma’s most successful mid-cap. Not long ago, Laboratories Servier was considered a somewhat mysterious and opaque actor on the world…
Due to high unmet medical need, oncology is set to remain as the number one therapeutic area globally in the coming years. France has traditionally been a leader in this…
AFKLM Cargo’s Director Pharma, Renate de Walle and Sales & Business Developer Manager Pharma France, Fabrice Panza speak about AFKLM Cargo recently achieved IATA Centre of Excellence for Independent Validators…
Lyon’s innovative roots, favourable location, educational excellence, and collaborative culture are all helping to make the city a premium life science, pharmaceuticals and biotech hub, not just in France, but globally. The…
Philippe Choukroun (PC) and Patricia Hatesuer (PH) of AAA speak about the Alsace region in France and the attractiveness of the life science cluster within the tri-national Biovalley area. They…
France provides a unique environment for dermo-cosmetics companies such as Pierre Fabre, Uriage, and Galderma to thrive in terms of the industry’s historical legacy in the country, abundant natural resources, and a…
France has a rich history in innovation, especially in the medical devices sector, but has not been able to produce a giant in the sector to compare with the global impact of…
Orange Healthcare CEO Elie Lobel discusses the importance of digitalization to the healthcare industry, major challenges, and the tremendous work that has already been done in the e-health regulatory field…
See our Cookie Privacy Policy Here
